Welcome!This home page contains the Supplementary Materials supporting the current series of publications titled:
"Autocratic origins of disease?" and "Therapeutic exploitation of expression variability: optimization of cancer radioisotope therapy"
The manuscripts share most of the supporting files and the differences are specified in the Supplementary Materials in Word format, describing each manuscript individually.
Also see below the supporting data for the earlier article titled: "Successful anti-cancer targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets"
S1.1 Initial large-scale project data on normal expression (Human Body Index):
GSE3526_series-1
GSE3526_series-2
GSE7307 Human body index-1
GSE7307 Human body index-2
GSE7307 Human body index-3
S1.2 Initial large-scale project data on cancer expression (EXPO project):
GSE2109-1
GSE2109-2
GSE2109-3
GSE2109-4
GSE2109-5
GSE2109-6
GSE2109-7
GSE2109-8
GSE2109-9
S1.3 Initial gene expression data - small scale projects:
GDS1249 Dendritic cells GDS1439 Prostate, benign and cancer GDS1553 Umbilical vein endothelial cells GDS1579 Leucocytes generic
GDS1665 Thyroid norm and cancer
GDS1673 Normal lung
GDS1732 Thyroid, normal vs tumor
GDS1973 Prostate normal
GDS2118 CD34+ progenitors from a bone marrow
GDS2216 Monocyte-derived dendritic cells
GDS2221-monocyte derived dendritic cells
GDS1439 Prostate, benign and cancer
GDS2431-CD34+ Hematopoetic progenitor cells, differentiation
GDS2609 colon mucos, normal and early cancer
GDS2611 Epidermal keratinocytes
GDS2615 Bronchial mucocilial cells
GDS2628 Bronchial muscle cells
GDS2635 Breast, normal and cancer, micodissected
GDS2697 Normal sperm
GDS2611 Proliferative endometrium normal
GSE2125 Alveolar macrophages
GSE2817 Glyoma
GSE3045 Astrocytes
GSE3141 Primary lung tumors
GSE3325 Prostate, normal, cancer and metastatic
GDS3678 Thyroid norm vs cancer
GSE4452 Multiple myeloma untreated
GSE4587 Normal skin vs melanoma
GSE4757 Brain, normal vs Alzheimer’s
GSE4888 Endometrium normal
GSE4845 melanoma
GSE5060_GPL570 Airway epithelium, smokers vs non_smokers
GSE5079 Astrocytes
GSE5372 Large airway epithelium, pre_ and post_ trauma
GSE5504 Normal monocytes
GSE5850 Normal oocytes
GSE6090 Dendritic cells
GSE6281 Skin
GSE6798 Muscle normal vs disease
GSE6338 Peripheral T_cell lymphoma
GSE8672 Lymphocytes
GSE9452 Colon mucosa normal vs inflamed
GSE9647 huvec endothelial cells
GSE9884 Bone marrow mesenchimal stem cells
GSE6872 Normal sperm
GSE7023 Normal renal and cancer
GSE7476 Bladder norm and cancer
GSE7896 Embryonic stem cells
GSE7846 Endometrium normal and hyperplasia
GSE8302 Normal hepatocytes
GSE8514 Normal adrenal gland
GSE8668 Neutrophils normal
GSE8671 Normal colon mucosa and adenoma
GSE7807 Normal monocytes
S2.1 Normal expression, individual tissue environments:
Accumbens
Adipose tissue
Adipose tissue omental
Adrenal gland
Amygdala
Anja cells
Aorta
B-cell resting
Bone marrow
Breast
Bronchus
Caudate
Colon
Coronary artery
Corpus calosum
Dorsal root ganglia
Endometrium
Esophagus
Fallopian tube
GDS1439 Prostate
GDS1673 Normal lung
GDS1973 Prostate normal
GDS2118-CD34+ Progenitors from a bone marrow
GDS2609 Colon mucos, normal vs early cancer
GDS2635 Normal vs cancer, microdissected
Glia, normal vs cancer
GSE3678 Thyroid norm vs cancer
GSE4452 Multiple myeloma untreated
GSE4845 melanoma, norm vs cancer
GDS2615 Bronchial mucocilial cells
GDS3045 Astrocytes
GDS2737 Proliferative endometrium normal
GSE4888 Endometrium normal
GSE5060 Airway epithelium
GSE5372 Large airway epithelium
GSE5850 Normal oocytes
GSE7807 Normal monocytes
GSE7896 Embryonic stem cells
GSE8514 Normal adrenal gland
GSE8668 Neutrophils normal
GSE8671 Normal colon mucosa, adenoma excluded
GSE9894 Bobe marrow mesenchimal stem cells
Heart Atrium
Heart Ventricle
Hep G2 cells
Hippocampus
Huvec cell lines
Hypothalamus
Joint tissue sinovium
Kidney
Liver
Liver normal
Lung
Lymph nodes
Medulla
Midbrain
Myometrium
Nipple cross section
Nodose nucleus
Occipital lobe
Oral mucosa
Oral mucosa-1
Ovary
Parietal lobe
Penis normal
Pharyngeal mucosa
Pituitary
Prifrontal cortex
Prostate
Putamen
Salivary gland
Skeletal muscle
Skin
Small intestine
Spinal cord
Spleen
Stomach normal
Substantia nigra
Synovial membrane
Temporal lobe
Testes
Thalamus
Thyroid gland
Tongue normal
Tonsil
Trachea
Trigeminal ganglia
Vagina
Ventral tegmental area
Vestibular nuclei superior
Vulva normal
S2.2 Cancer expression, individual tissue environments:
Abdominal wall mass and peritoneum
Appendix area
Bladder
Bone and cartilage
Brain
Breast
Breast-2
Breast-3
Endometrium
Esophagus
Fallopian
GSE2817 Glyoma
GSE4452 Multiple myeloma untreated
GSE4845 Melanoma
Ileum and small intestine
Jejunum
Kidney-2
Kidney-3
Liver cancer
Lung-2
Lung-3
Lung cancer
Lymphatic node
Myometrium cancer
Omentum
Ventral tegmental area
Ovary-2
Omentum
Muscle
Pancreas
Parotid gland
Pelvic mass
Penis
Prostate
Rectosigmoid
Skin
Rectum
Renal pelvis
Retroperitoneal mass and peritoneum
, Spleen
Stomach
Stomach
Testis
Thyroid
Tongue
Ureter
Uterus
Uterus-2
Vulva cancer
S2.3 Paired datasets, comparing cancer and norm for the same tissue environments:
Adipose tissue, norm vs cancer
Adrenal gland, norm vs cancer
Bladder, norm vs cancer
Breast, norm vs cancer
Colon, norm vs cancer
Endometrium, normal vs cancer
Esophagus, normal vs cancer
Fallopian tube, normal vs cancer
GDS2609 Colon mucos, normal vs early cancer
GDS2635 Normal vs cancer, microdissected
Glia, normal vs cancer
GSE3678 Thyroid norm vs cancer
GSE4452 Multiple myeloma untreated
GSE4845 melanoma, norm vs cancer
Ileum and small intestine, norm vs cancer
Kidney, norm vs cancer
Liver, normal vs cancer
Lung, normal vs cancer
Lymphatic node, norm vs cancer, lymphoma
Normal skin vs melanoma
Myometrium, normal vs cancer
Ovary, normal vs.cancer
Pancreas, norm vs cancer
Parotid gland, norm vs cancer
Prostate, norm vs cancer
Small intestine, norm vs cancer
Stomach, normal vs cancer
Thyroid gland, norm vs cancer
Tongue, normal and cancer
Urethra, normal vs cancer
Vagina, normal vs cancer
Vulva, normal vs cancer
S2.4 Integrated panel of differential expression:
Variation in different classes of anti-cancer targets
S3.1 Large-scale panel of normal variability data:
S3 Read-me
S3.1.1 Variabilities and expression values, combined panel
S3.1.2 Expression values
S3.1.3 Variabilities, Z scores
S3.1.4 Variabilities, Q-Q plot
S3.1.5 Variabilities, high Z scores only
S3.1.6 Panel avearged variability
S3.2.Comparison of variability in norm and cancer: initial datasets combined in the panel:
Adrenal gland, normal vs cancer
Lung, normal vs cancer
Prostate, normal vs cancer
Small intestine, normal vs cancer
GSE4452 Multiple myeloma, normal vs cancer
Melanoma, normal skin vs cancer
Stomach, normal vs cancer
S3.3 Comparison of variability in norm and cancer: variability in the form of MAX/MIN and RELVAR is computed for norm and cancer, MAX//MIN and RELVAR are computed and aligned with disease information:
MAX/MIN and RELVAR are computed for the panel of normal and cancer expression data
MAX/MIN and RELVAR in cancer and norm are computed and aligned with data covering multiple diseases
S3.4 Comparison of multiple expression parameters in norm and cancer, MAX/MIN, RELVAR, DEXCON, Expression and large-scale variability panel data are all integrated and aligned with disease information:
Diverse expression parameters are aligned with different classes of anti-cancer targets
S4. Ontological analysis of the highest and lowest variability classes:
Ontological analysis of the highest and lowest variability classes
"Successful anti-cancer targets able to pass FDA review dmonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets" by A. Mayburd, I. Golovchikova and J. Mulshine
Contents and brief description of this site
Rationale, Methodology and Discussion
The contents of the Excel files below correspond to RD (Raw data) abbreviation in the main manuscript.
List of genes used in this project
(for scoring system 1):
Template
Code to the programs:
Utils.pas
Datalookup.dpr
uMain.dfm
uMain.pas
Eliminator.dpr
uMain.dfm
uMain.pas
Highlighter.dpr
uMain.dfm
uMain.pas
Patcher.dpr
uMain.dfm
uMain.pas
StatData
uMain.dfm
uMain.pas
Terminator.dpr
uMain.dfm
uMain.pas
Classes of targets, asignment of training and testing sets S2: S2 Subdivision of successful class into training and testing sets
Successful developing and proposed targets S2: S2 Successful, developing and proposed targets
DEXCON score introduced S3: S3 DEXCON score introduced
INTVAR score introduced S4: S4 Interprobe variance assembly S4 Interprobe variance assembly- CANCER subpanel S4 Intvar scores for the total panel
SURV score introduced S5: S5 Tertiary clustering cancer panel S5 Tertiary clustering normalcy panel S5 Tertiary clustering normalcy panel - table of contents S5 Survival coefficient, its derivation and analysis
Correlative profiles and derivation of FU-test S6: S6 Breast cancer dataset correlative profiles S6 Glioma dataset correlative profiles S6 Myeloma dataset correlative profiles S6D Features assembled for individual probe-sets
Scoring system 1 and 2 aggregated and applied to Expanded dataset, S7: S7A Integration in a linear classifier S7B Relative functional enrichment
Bonus-pnalty coefficient as a function of score, aggregated system 1 and 2, S8: S8 Bonus-penalty coefficient in integrated classifier
Cross-validation data S9: S9 Cross-validaton, scoring system 1 S9 Cross-validation scoring system 1 and 2 combined
Exclusion of bias S10: S10 Exclusion of bias
ROC curve analysis S11: S11 ROC curve, system 1 S11 ROC curve, aggregated system (1+2)
Validation by literature search S12: S12 Validation by Pubmed analysis
Proof that overfit is absent S13: S13 Overfit control
Study of Alzheimer's disease S14: S14 Targets for Alzheimer's disease treatment
How many anti-cancer targets? S15:
S15 Suggested anti-cancer targets 1
S15 Suggested anti-cancer targets 2